URGN - NASDAQ
UroGen Pharma Ltd.
$27.60
+4.0%UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
At a Glance
Live SnapshotUroGen Pharma Ltd. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
UroGen Pharma Ltd. Cash Flow Statement
URGN • NASDAQ
| UroGen Pharma Ltd. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-153.5M | -126.9M | -102.2M | -109.8M | -110.8M | -128.5M | -105.1M | -75.7M | -20M | -1.9M | -12.7M | -4.5M | -3.3M | |
2.4M | 1.2M | 1.7M | 1.8M | 1.8M | 2M | 1.3M | 417K | 207K | 213K | 113K | 30K | 18K | |
0.0 | 0.0 | 0.0 | 0.0 | 15.3M | 439K | -572K | 0.0 | 0.0 | 0.0 | 240K | 0.0 | 0.0 | |
12M | 13.1M | 9.3M | 10.6M | 23.1M | 28M | 30M | 30.6M | 6.3M | 2M | 449K | 293K | 541K | |
4.6M | 10.9M | 11.5M | 16.1M | -1.2M | -1.5M | -910K | 100K | 165K | 2.7M | 4.1M | 198K | 177K | |
-27.9M | 4.9M | 3.3M | -6.3M | -13.1M | -6.4M | 4.3M | 7.2M | 3.8M | 1.2M | 609K | -162K | 13K | |
-162.4M | -96.8M | -76.4M | -87.6M | -84.9M | -105.9M | -71M | -37.3M | -9.6M | 4.2M | -7.2M | -4.1M | -2.6M | |
INVESTING ACTIVITIES | |||||||||||||
-289K | -295K | -194K | -254K | -752K | -1.2M | -325K | -560K | -271K | -695K | -301K | -24K | -57K | |
(0.0) | (0.0) | (0.0) | -1.3M | -4.8M | -94.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-77.4M | -128M | -49.8M | -63M | -51.9M | -29.7M | -197.7M | -54K | -36M | -24K | (0.0) | (0.0) | (0.0) | |
139.2M | 107.7M | 49.1M | 64.3M | 56.7M | 124.1M | 52.6M | 35.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 1.3M | 4.8M | 94.5M | -172K | -54K | -105K | -98K | 0.0 | 23K | -32K | |
(61.6M) | -20.6M | -953K | (1.1M) | (4.1M) | (93.2M) | -145.6M | (35.3M) | -36.4M | -793K | -301K | -1K | -89K | |
FINANCING ACTIVITIES | |||||||||||||
41.8M | 151.2M | 67.4M | 1.4M | -83K | 15.9M | 161.7M | 64.2M | 60.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.9M | 24.5M | 0.0 | 95.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 647K | 0.0 | |
0.0 | 19M | 49.6M | 0.0 | 72.4M | 674K | 3.6M | 2.2M | 744K | -9K | 0.0 | 4.3M | 3.5M | |
39.9M | 194.6M | 116.9M | 97.1M | 72.3M | 16.5M | 165.3M | 66.4M | 61.6M | -9K | 21.6M | 5M | 3.5M | |
CASH FLOW SUMMARY | |||||||||||||
-61M | 77.2M | 39.6M | 10.6M | -8.5M | 3.9M | -51.4M | 64.4M | 15.6M | 3.4M | 14.1M | 833K | 822K | |
173.1M | 95.8M | 56.2M | 45.6M | 54.1M | 50.2M | 101.6M | 37.2M | 21.4M | 18M | 3.9M | 3M | 2.2M | |
112.1M | 173.1M | 95.8M | 56.2M | 45.6M | 54.1M | 50.2M | 101.6M | 37M | 21.4M | 18M | 3.9M | 3M | |
-162.7M | -97.1M | -76.6M | -87.8M | -85.6M | -107.1M | -71.3M | -37.9M | -9.8M | 3.5M | -7.5M | -4.1M | -2.6M |
SEC Filings
URGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 27, 2025 | August 26, 2025 | 2025 |
Related Guides
Continue your URGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.